56.66
+8.13%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Heartflow
From its filings with the US Securities and Exchange Commission
Heartflow is based in San Francisco, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker HTFL. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $176.0m and a net loss of $116.8m. At that date it held total assets of $359.5m and shareholders' equity of $300.6m.
We provide software and artificial intelligence (“AI”) designed to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of December 31, 2025, our Heartflow Platform has been used to assess CAD in more than 600,000 patients, including 219,000 in 2025 alone. We believe that we are the most widely adopted AI-powered test for CAD. Our novel platform leverages AI and advanced computational fluid dynamics to create a personalized 3D model of a patient’s heart from a single coronary computed tomography angiography (“CCTA”), a specialized type of scan that provides detailed images of the heart’s arteries. Our Heartflow Platform delivers actionable insights on blood flow, stenosis, plaque volume and plaque composition thereby overcoming the limitations of traditional non-invasive imaging tests which rely on indirect measures of coronary disease and lead to higher false negative and false positive rates, as demonstrated by our PRECISE trial. We believe the differentiated accuracy and clinical utility of our Heartflow Platform, along with its ability to enhance workflows, will continue to support our growth and advance the “CCTA + Heartflow” pathway as the definitive standard for the non-invasive diagnosis and management of CAD.
Quoted from its 10-K, filed 18 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Technology
- Listed since
- 8 Aug 2025
- Employees
- 843
- Website
- heartflow.com ↗
- Head office
- 135 MAIN STREET, SUITE 1000, SAN FRANCISCO, CA, 94105
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Non-accelerated filer<br>Emerging growth company
Leadership
Pay as last reported
- Mr. William WeldonIndependent Chairman of the Board$65,000
- Mr. John FarquharPresident, Chief Executive Officer, Director, since 2021$2.3m
- Mr. Vikram VergheseChief Financial Officer$1.7m
- Dr. Campbell RogersChief Medical Officer$1.1m
- Dr. Nicholas DowningDirector
- Dr. Charles TaylorDirector$611,082
- Mr. Timothy BarabeIndependent Director$40,000
- Ms. Julie CullivanIndependent Director$40,000
- Mr. Jeffrey LightcapIndependent Director
- Dr. Wayne RileyIndependent Director$40,000
- Mr. Lonnie SmithIndependent Director$40,000
- Mr. Casey TanseyIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Heartflow Inc is a commercial-stage medical technology company with a focus on AI-driven solutions for coronary artery disease diagnosis.
- The company has developed a proprietary HeartFlow Platform using AI and computational fluid dynamics for personalized 3D heart modeling.
- Heartflow Inc has a clear product suite including Roadmap Analysis, FFRCT Analysis, and Plaque Analysis for CAD management.
Weaknesses
- The company is a commercial-stage entity with no historical financial data provided.
- Heartflow Inc has not yet generated revenue or profit data as it is a new IPO company.
- The company's IPO date is in the future (2025-08-08), indicating limited market presence.
Opportunities
- The growing demand for non-invasive diagnostic solutions in cardiovascular care presents a market opportunity.
- Advancements in AI technology could enhance the company's platform capabilities and market appeal.
- The Health Care Technology sector is expanding, offering potential for market growth and partnerships.
Threats
- The company faces competition from established medical technology firms in the Health Care sector.
- Regulatory challenges in the medical technology industry could impact product approvals and market access.
- The future IPO date (2025-08-08) introduces market volatility and uncertainty for investors.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.